除幽愈疡免煎颗粒联合含铋剂四联疗法治疗幽门螺杆菌感染相关脾虚湿热型慢性胃炎临床观察被引量：4

Clinical Observation of Chuyou Yuyang Mianjian Granules Combined with Bismuth-Based Quadruple Therapy in the Treatment of Helicobacter Pylori Infection-Associated Chronic Gastritis with Spleen-Deficiency and Dampness-Heat Syndrome

下载PDF

导出

摘要目的探讨除幽愈疡免煎颗粒联合含铋剂四联疗法治疗幽门螺杆菌(HP)感染相关脾虚湿热型慢性胃炎的临床疗效。方法选取医院2021年4月至2022年4月收治的HP感染相关脾虚湿热型慢性胃炎患者98例,按随机数字表法分为观察组和对照组,各48例。两组患者均予含铋剂四联疗法治疗,观察组患者加服除幽愈疡免煎颗粒,两组均治疗14 d。结果治疗后1个月,观察组患者HP根除率为91.67%,显著高于对照组的66.67%(P<0.05)。治疗后3个月,观察组总有效率为87.50%,显著高于对照组的64.58%(P<0.05)。与对照组比较,观察组患者治疗后的胃胀痛、烧心,纳差、口渴不欲饮,口中异味等主症及其总积分均显著低于对照组;反酸、嗳气、恶心,身重困倦,大便不爽黏腻症状等次症及其总积分均显著低于对照组;血清白细胞介素(IL)-1β、IL-6、IL-8、肿瘤坏死因子-α、核因子-κB水平均显著低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(10.42%比6.25%,P>0.05)。结论除幽愈疡免煎颗粒联合含铋剂四联疗法治疗HP感染相关脾虚湿热型慢性胃炎,可有效缓解患者的临床症状,减轻炎性反应程度。 Objective To investigate the clinical efficacy of Chuyou Yuyang Mianjian Granules combined with bismuth-based quadruple therapy in the treatment of Helicobacter pylori(HP)infection-associated chronic gastritis with spleen-deficiency and dampness-heat syndrome.Methods A total of 98 patients with HP infection-associated chronic gastritis with spleen-deficiency and dampness-heat syndrome admitted to the hospital from April 2021 to April 2022 were selected and divided into the observation group and the control group by the random number table method,with 48 cases in each group.The patients in the two groups were given the bismuth-based quadruple therapy,on this basis,the patients in the observation group were treated with Chuyou Yuyang Mianjian Granules.Both groups were treated for 14 d.Results One month after treatment,the HP eradication rate in the observation group was 91.67%,which was significantly higher than 66.67%in the control group(P<0.05).Three months after treatment,the total effective rate in the observation group was 87.50%,which was significantly higher than 64.58%in the control group(P<0.05).Compared with those in the control group,the scores of main symptoms including stomach bloating and pain,heartburn,poor appetite,thirst and reluctance to drink,bad breath in the mouth and the total score in the observation group were significantly lower than those in the control group after treatment(P<0.05).Compared with those in the control group,the scores of secondary symptoms including acid reflux,belching,nausea,heavy body,drowsiness,unpleasant and sticky stools and the total score in the observation group were significantly lower than those in the control group after treatment(P<0.05).Compared with those in the control group,the interleukin(IL)-1β,IL-6,IL-8,tumor necrosis factor-α(TNF-α),nuclear factor-κB(NF-κB)levels in serum in the observation group were significantly lower than those in the control group after treatment(P<0.05).The incidence of adverse reactions in the observation group was similar t

作者杨芳许琰杰臧海洋沈文葛桂萍 YANG Fang;XU Yanjie;ZANG Haiyang;SHEN Wen;GE Guiping(Nantong Hospital,Nanjing University of Chinese Medicine,Nantong,Jiangsu,China 226000)

机构地区南京中医药大学附属南通医院

出处《中国药业》 CAS 2023年第14期104-108,共5页 China Pharmaceuticals

基金江苏省中医药科技发展计划项目[YB2020066]。

关键词幽门螺杆菌慢性胃炎脾虚湿热证铋剂除幽愈疡免煎颗粒四联疗法炎性因子临床疗效 Helicobacter pylori chronic gastritis spleen-deficiency and dampness-heat syndrome bismuth Chuyou Yuyang Mianjian Granules quadruple therapy inflammatory factor clinical efficacy